+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07246863

Randomized Trial of Visugromab and Nivolumab With or Without Docetaxel Compared to Docetaxel Alone for Second-Line Treatment of Metastatic Non-Squamous NSCLC

Led by CatalYm GmbH · Updated on 2026-10-26

131

Participants Needed

36

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the anti-GDF-15 antibody Visugromab in combination with Nivolumab and Docetaxel for participants with metastatic non-squamous non-small cell lung cancer NSCLC who have not responded to prior first-line treatment including a checkpoint inhibitor. This phase 2b, randomized, placebo-controlled, and double-blinded trial aims to find signals of effectiveness and safety across different dose levels and treatment combinations. The study includes three parts an open-label safety run-in, followed by a randomized phase with four treatment groups. Participants receive intravenous infusions every 3 weeks of either Visugromab at two dose levels plus Nivolumab with Docetaxel, Visugromab at a higher dose plus Nivolumab with placebo, or double placebo with Docetaxel. After initial treatment of a subset of participants, an interim safety and efficacy analysis is performed before continuing treatment of remaining participants. Participants will be closely monitored with regular assessments over months, including measuring tumor response using Objective Response Rate ORR for up to 36 months, and tracking safety events for up to 60 months. Additional measures include progression-free survival, overall survival, symptom questionnaires, and drug concentrations. This comprehensive follow-up helps researchers understand treatment effects and participant well-being over time.

CONDITIONS

Brief Title

Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

Research Team

L

Lena Lemke, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here